JP6176924B2 - 医薬製剤 - Google Patents

医薬製剤 Download PDF

Info

Publication number
JP6176924B2
JP6176924B2 JP2012532657A JP2012532657A JP6176924B2 JP 6176924 B2 JP6176924 B2 JP 6176924B2 JP 2012532657 A JP2012532657 A JP 2012532657A JP 2012532657 A JP2012532657 A JP 2012532657A JP 6176924 B2 JP6176924 B2 JP 6176924B2
Authority
JP
Japan
Prior art keywords
hcg
mol
sialylation
rhcg
sialic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012532657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506708A (ja
Inventor
コッティングハム，イアン
プラクシン，ダニエル
ホワイト，リチャード，ボイド
Original Assignee
フェリング ベスローテン フェンノートシャップ
フェリング ベスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェリング ベスローテン フェンノートシャップ, フェリング ベスローテン フェンノートシャップ filed Critical フェリング ベスローテン フェンノートシャップ
Publication of JP2013506708A publication Critical patent/JP2013506708A/ja
Application granted granted Critical
Publication of JP6176924B2 publication Critical patent/JP6176924B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012532657A 2009-10-05 2010-10-04 医薬製剤 Active JP6176924B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09252360.4 2009-10-05
EP09252360 2009-10-05
PCT/GB2010/001854 WO2011042688A1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015219480A Division JP6310440B2 (ja) 2009-10-05 2015-11-09 医薬製剤

Publications (2)

Publication Number Publication Date
JP2013506708A JP2013506708A (ja) 2013-02-28
JP6176924B2 true JP6176924B2 (ja) 2017-08-09

Family

ID=41471027

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012532657A Active JP6176924B2 (ja) 2009-10-05 2010-10-04 医薬製剤
JP2015219480A Active JP6310440B2 (ja) 2009-10-05 2015-11-09 医薬製剤
JP2017205012A Expired - Fee Related JP6580104B2 (ja) 2009-10-05 2017-10-24 医薬製剤
JP2019154226A Active JP7292153B2 (ja) 2009-10-05 2019-08-27 医薬製剤
JP2021114833A Active JP7196244B2 (ja) 2009-10-05 2021-07-12 医薬製剤
JP2023025781A Pending JP2023075144A (ja) 2009-10-05 2023-02-22 医薬製剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015219480A Active JP6310440B2 (ja) 2009-10-05 2015-11-09 医薬製剤
JP2017205012A Expired - Fee Related JP6580104B2 (ja) 2009-10-05 2017-10-24 医薬製剤
JP2019154226A Active JP7292153B2 (ja) 2009-10-05 2019-08-27 医薬製剤
JP2021114833A Active JP7196244B2 (ja) 2009-10-05 2021-07-12 医薬製剤
JP2023025781A Pending JP2023075144A (ja) 2009-10-05 2023-02-22 医薬製剤

Country Status (25)

Country Link
US (5) US8975226B2 (enExample)
EP (2) EP2486051B1 (enExample)
JP (6) JP6176924B2 (enExample)
KR (7) KR102213154B1 (enExample)
CN (1) CN107050434B (enExample)
AR (2) AR079876A1 (enExample)
AU (1) AU2010304922B2 (enExample)
BR (1) BR112012007990A2 (enExample)
CA (1) CA2776790A1 (enExample)
DK (1) DK2486051T3 (enExample)
ES (2) ES3036152T3 (enExample)
HR (1) HRP20200941T1 (enExample)
HU (1) HUE050793T2 (enExample)
IL (3) IL218548A (enExample)
IN (1) IN2012DN02073A (enExample)
JO (1) JOP20200039A1 (enExample)
LT (1) LT2486051T (enExample)
MX (1) MX2012003951A (enExample)
PL (1) PL2486051T3 (enExample)
PT (1) PT2486051T (enExample)
RS (1) RS60413B1 (enExample)
RU (2) RU2724528C2 (enExample)
SI (1) SI2486051T1 (enExample)
TW (2) TWI532495B (enExample)
WO (1) WO2011042688A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018076296A (ja) * 2009-10-05 2018-05-17 フェリング ベスローテン フェンノートシャップ 医薬製剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) * 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN104919046A (zh) 2012-12-10 2015-09-16 生化学工业株式会社 新重组因子c、其制造方法、及内毒素的测定法
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
RS61163B1 (sr) 2015-04-24 2021-01-29 Ferring Bv Postupak proizvodnje gonadotrofina
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
WO2019211153A1 (en) * 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
AU2021215893A1 (en) * 2020-02-05 2022-08-25 Novartis Ag CHO cell expressing IL-15 heterodimers
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法
TWD234354S (zh) * 2023-09-19 2024-10-21 日商富士股份有限公司 (日本) 轉移輔助機
KR102821987B1 (ko) * 2024-10-24 2025-06-26 에이디텍 주식회사 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE69524456T2 (de) * 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU747179B2 (en) 1997-06-25 2002-05-09 Merck Serono Sa Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
CA2372714A1 (en) * 1999-05-07 2000-11-16 Stephen Franks The use of luteinizing hormone in the induction of pauci-or unifolliculogenesis
PL205149B1 (pl) * 2000-02-22 2010-03-31 Serono Lab Sposób przygotowania rekombinowanej hCG
HRP20040087A2 (en) 2001-09-12 2004-12-31 Applied Research Systems USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
IL161235A0 (en) * 2001-10-22 2004-09-27 Applied Research Systems Fsh composition, its preparation and use
EA008220B1 (ru) * 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
JP2006522151A (ja) * 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
CA2522345A1 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
DK1654353T3 (da) * 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
ATE476666T1 (de) * 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CA2557725C (en) * 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
JP2008532966A (ja) * 2005-03-11 2008-08-21 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不活性出発物質からの生理活性糖タンパク質の生成
JP2009504985A (ja) 2005-08-15 2009-02-05 シーメンス ヴィディーオー オートモーティヴ コーポレイション ディーゼル車排気への炭化水素計量弁
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) * 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018076296A (ja) * 2009-10-05 2018-05-17 フェリング ベスローテン フェンノートシャップ 医薬製剤
JP2020000246A (ja) * 2009-10-05 2020-01-09 フェリング ベスローテン フェンノートシャップ 医薬製剤
JP2021176867A (ja) * 2009-10-05 2021-11-11 フェリング ベスローテン フェンノートシャップ 医薬製剤
JP7196244B2 (ja) 2009-10-05 2022-12-26 フェリング ベスローテン フェンノートシャップ 医薬製剤
JP7292153B2 (ja) 2009-10-05 2023-06-16 フェリング ベスローテン フェンノートシャップ 医薬製剤

Also Published As

Publication number Publication date
KR101804479B1 (ko) 2017-12-05
JOP20200039A1 (ar) 2022-10-30
ES2798258T3 (es) 2020-12-10
KR20190028823A (ko) 2019-03-19
JP6580104B2 (ja) 2019-09-25
KR101987982B1 (ko) 2019-06-11
AR125991A2 (es) 2023-08-30
TW201632198A (zh) 2016-09-16
KR102213154B1 (ko) 2021-02-05
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
US20200247863A1 (en) 2020-08-06
AR079876A1 (es) 2012-02-29
JP2013506708A (ja) 2013-02-28
AU2010304922A1 (en) 2012-03-29
RU2016118236A3 (enExample) 2019-09-18
PT2486051T (pt) 2020-06-17
US20220340634A1 (en) 2022-10-27
RU2588650C2 (ru) 2016-07-10
RU2016118236A (ru) 2018-10-29
KR20210141771A (ko) 2021-11-23
US10526390B2 (en) 2020-01-07
US8975226B2 (en) 2015-03-10
KR20230012104A (ko) 2023-01-25
CN107050434A (zh) 2017-08-18
MX2012003951A (es) 2012-05-29
JP2018076296A (ja) 2018-05-17
JP2020000246A (ja) 2020-01-09
CN107050434B (zh) 2021-07-27
KR20190067256A (ko) 2019-06-14
IL267556A (en) 2019-08-29
JP2021176867A (ja) 2021-11-11
JP6310440B2 (ja) 2018-04-11
CN102549011A (zh) 2012-07-04
IL250733A0 (en) 2017-04-30
US11292824B2 (en) 2022-04-05
PL2486051T3 (pl) 2020-09-07
LT2486051T (lt) 2020-07-10
KR102489143B1 (ko) 2023-01-13
US9676835B2 (en) 2017-06-13
TW201113030A (en) 2011-04-16
JP2016074680A (ja) 2016-05-12
IN2012DN02073A (enExample) 2015-08-21
EP2486051B1 (en) 2020-03-25
KR20170133531A (ko) 2017-12-05
BR112012007990A2 (pt) 2017-07-25
DK2486051T3 (da) 2020-06-22
US20140249082A1 (en) 2014-09-04
HUE050793T2 (hu) 2021-01-28
KR20210014767A (ko) 2021-02-09
ES3036152T3 (en) 2025-09-15
EP3611185A1 (en) 2020-02-19
JP2023075144A (ja) 2023-05-30
US12234272B2 (en) 2025-02-25
SI2486051T1 (sl) 2020-08-31
AU2010304922B2 (en) 2014-11-06
JP7196244B2 (ja) 2022-12-26
WO2011042688A1 (en) 2011-04-14
EP2486051A1 (en) 2012-08-15
RU2724528C2 (ru) 2020-06-23
JP7292153B2 (ja) 2023-06-16
IL218548A (en) 2017-03-30
RU2012112907A (ru) 2013-11-10
US20180030107A1 (en) 2018-02-01
HRP20200941T1 (hr) 2020-09-18
IL218548A0 (en) 2012-05-31
EP3611185B1 (en) 2025-04-30
TWI532495B (zh) 2016-05-11
US20130023476A1 (en) 2013-01-24
IL250733B (en) 2019-07-31
RS60413B1 (sr) 2020-07-31
CA2776790A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
JP7196244B2 (ja) 医薬製剤
TWI488640B (zh) 藥學製劑
JP6336557B2 (ja) 医薬製剤
HK40020346A (en) Pharmaceutical preparation
CN102549011B (zh) 包含重组hcg的药物制剂
Class et al. Patent application title: Pharmaceutical Preparation Comprising Recombinant HcG Inventors: Ian Cottingham (St. Prex, CH) Daniel Plaksin (St. Prex, CH) Richard Boyd White (San Diego, CA, US) Assignees: Ferring BV
HK1174338B (en) Pharmaceutical preparation comprising recombinant hcg
HK1174338A (en) Pharmaceutical preparation comprising recombinant hcg

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160324

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170711

R150 Certificate of patent or registration of utility model

Ref document number: 6176924

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250